Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules

May 29, 2026 updated by: M.D. Anderson Cancer Center
To observe the outcomes of nsPFA therapy to treat benign thyroid nodules.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Primary Objectives

• To evaluate the thyroid nodule volume changes over time in participants undergoing nsPFA as part of routine clinical care

Secondary Objectives

  • To determine changes in health-related quality of life changes following ultrasound-guided nsPFA
  • To evaluate the ultrasound features of thyroid nodules over time following ultrasound-guided nsPFA.
  • To assess the incidence and nature of complications following ultrasound-guided nsPFA, categorized into Minor and Major complications.

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • MD Anderson Cancer Center
        • Contact:
        • Principal Investigator:
          • Victoria E Banuchi, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

MD Anderson Cancer Center

Description

Eligibility Criteria

  • Scheduled to undergo ultrasound guided nsPFA as standard of care
  • Age 18 to 80 years.
  • Capable of providing independent consent.

  • Presence of biopsy-confirmed benign thyroid nodule , defined as one of the following:

    • Benign FNA X 2 or
    • Benign US guided FNA X 1 + benign thyroid nodule ultrasound appearance (TI-RADS 2) or
    • Benign FNA X 1 and radiographic/laboratory evidence of functional nature
  • Nodule measuring >2cm in greatest dimension
  • Presence of compressive symptoms reasonably attributable to thyroid nodule (i.e. pressure sensation, dysphagia, dysphonia, respiratory distress)
  • No abnormal cervical lymph nodes during screening visit .

Exclusion Criteria

  • Age <18
  • Patients considered unsuitable for nsPFA by the treating physician

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Quality-of-life Questionnaire
Time Frame: Through study completion; an average of 1 year
Through study completion; an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Victoria E Banuchi, MD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 14, 2025

Primary Completion (Estimated)

August 31, 2028

Study Completion (Estimated)

August 31, 2030

Study Registration Dates

First Submitted

November 7, 2025

First Submitted That Met QC Criteria

November 7, 2025

First Posted (Actual)

November 10, 2025

Study Record Updates

Last Update Posted (Actual)

June 1, 2026

Last Update Submitted That Met QC Criteria

May 29, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-0483
  • NCI-2025-08362 (Other Identifier: NCI-CTRP Clinical Registry)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thyroid Nodules

Clinical Trials on Questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe